MARAVAI LIFESCIENCES HOLDINGS, INC.(MRVI)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,696 of 2,961 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
MRVI Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores MRVI at 24.4/100 on a 32-signal composite quality model, placing it at rank #2,696 of 2,961 stocks — the bottom half of the AI-ranked universe. MRVI scores in the top quartile across institutional flow (94.7). Areas of concern include revenue growth (6.8) and profitability (13.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 11.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), MARAVAI LIFESCIENCES HOLDINGS, INC. reports quarterly revenue of $51.4M, net income of $-12.4M, free cash flow of $3.6M. Top institutional holders of MRVI by reported 13-F value include GTCR, BlackRock, BRAIDWELL, based on the most recent SEC filings. MRVI trades on the Nasdaq exchange and files with the SEC under CIK 1823239. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MRVI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for MARAVAI LIFESCIENCES HOLDINGS, INC. directly from SEC EDGAR. MARAVAI LIFESCIENCES HOLDINGS, INC.'s 13F Pro composite quality score has ranged between 14 and 85 since 2022, currently 24.4 — a declining long-term trajectory across 64 quarterly and live scoring snapshots.
Revenue
Q2 2026
$51.4M
Net Income
Q2 2026
$-12.4M
Free Cash Flow
Q2 2026
$3.6M
ROIC
Q2 2026
-17.1%
D/E Ratio
Q2 2026
0.72
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
-28.3% YoYNet Income
+9.7% YoYOperating Income
+8.6% YoYEPS (Diluted)
+14.3% YoYTotal Assets
-23.6% YoYTotal Debt
-1.4% YoYOp. Cash Flow
-871.2% YoYFree Cash Flow
-218.7% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $185.7M -28.3% | $259.2M -10.3% | $288.9M -67.3% | $883.0M +10.5% | $799.2M +181.3% | $284.1M |
| Net Income | $-130.8M +9.7% | $-144.8M -21.7% | $-119.0M -154.1% | $220.2M +21.0% | $182.0M +104.6% | $89.0M |
| Operating Income | $-215.3M +8.6% | $-235.6M -644.5% | $-31.6M -105.5% | $574.2M +3.5% | $554.6M +362.6% | $119.9M |
| EPS (Diluted) | $-0.90 +14.3% | $-1.05 -16.7% | $-0.90 -153.9% | $1.67 +7.1% | $1.56 -33.9% | $2.36 |
| Total Assets | $770.6M -23.6% | $1.01B -32.2% | $1.49B -34.8% | $2.28B +19.0% | $1.92B +51.0% | $1.27B |
| Total Debt | $297.2M -1.4% | $301.4M -43.1% | $529.6M -0.6% | $532.9M -0.7% | $536.6M -0.7% | $540.6M |
| Operating Cash Flow | $-57.6M -871.2% | $7.5M -94.1% | $126.2M -76.4% | $536.0M +45.4% | $368.6M +142.2% | $152.2M |
| Free Cash Flow | $-70.7M -218.7% | $-22.2M -136.6% | $60.7M -88.3% | $518.9M +46.7% | $353.7M +179.0% | $126.8M |
Get alerted when MRVI's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for MARAVAI LIFESCIENCES HOLDINGS, INC. including:
Top Institutional Holders of MRVI
GTCR LLC
$125.7M20,150,005 shBlackRock, Inc.
$62.2M9,970,780 shBRAIDWELL LP
$54.3M8,702,921 sh12 West Capital Management LP
$44.1M7,060,195 shMILLENNIUM MANAGEMENT LLC
$40.6M6,508,220 shVANGUARD CAPITAL MANAGEMENT LLC
$33.0M5,283,665 shOphir Asset Management Pty Ltd
$30.1M4,826,698 shRENAISSANCE TECHNOLOGIES LLC
$28.7M4,606,491 shDEUTSCHE BANK AG\
$26.9M4,304,927 shFirst Eagle Investment Management, LLC
$22.9M3,671,287 sh
| Fund | Value | Shares |
|---|---|---|
| GTCR LLC | $125.7M | 20,150,005 |
| BlackRock, Inc. | $62.2M | 9,970,780 |
| BRAIDWELL LP | $54.3M | 8,702,921 |
| 12 West Capital Management LP | $44.1M | 7,060,195 |
| MILLENNIUM MANAGEMENT LLC | $40.6M | 6,508,220 |
| VANGUARD CAPITAL MANAGEMENT LLC | $33.0M | 5,283,665 |
| Ophir Asset Management Pty Ltd | $30.1M | 4,826,698 |
| RENAISSANCE TECHNOLOGIES LLC | $28.7M | 4,606,491 |
| DEUTSCHE BANK AG\ | $26.9M | 4,304,927 |
| First Eagle Investment Management, LLC | $22.9M | 3,671,287 |
Companies Similar to MRVI
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Maze Therapeutics, Inc.
Ginkgo Bioworks Holdings, Inc.
NEKTAR THERAPEUTICS
C4 Therapeutics, Inc.
Vanda Pharmaceuticals Inc.
RECURSION PHARMACEUTICALS, INC.
Roivant Sciences Ltd.
RxSight, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put MRVI on your watchlist
Track score changes the day MARAVAI LIFESCIENCES HOLDINGS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is MRVI a good stock to buy?
13F Pro's AI-powered analysis of MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MRVI are available on the MRVI stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. MRVI is classified as a small company.
Which hedge funds own MRVI?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MRVI. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of MARAVAI LIFESCIENCES HOLDINGS, INC.'s investment landscape.